Targeting GI tract diseases by oral administration
Affilogic is developing a Nanofitin®-based molecule for inflammatory bowel disorders via oral route.
Affilogic capitalizes on the high stability of the Nanofitin® scaffold to develop a targeted therapy deliverable orally, addressing a proinflammatory pathway (undisclosed) involved in inflammatory bowel disorders. We have already validated the neutralizing activity of our Nanofitin®-based molecule in-vitro, as well as its stability when exposed to simulated gastric and intestinal fluids. We also proved that this Nanofitin®-based molecule is able to engage the target in the gastrointestinal tract in vivo in mice.
Satellite projects :
Gut–2–Blood : Affilogic has developed a Nanofitin®-based shuttle to enhance bioavailibility of a molecule fused to such shuttle. The mechanism of action relies on a receptor-mediated transcytosis, using the Leptin receptor (LepR). We have shown efficient gut crossing in an ex-vivo porcine intestinal model (Masloh et al., Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model, Pharmaceutics 2024).